1. Home
  2. ONTF vs OMER Comparison

ONTF vs OMER Comparison

Compare ONTF & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ONTF
  • OMER
  • Stock Information
  • Founded
  • ONTF 1998
  • OMER 1994
  • Country
  • ONTF United States
  • OMER United States
  • Employees
  • ONTF N/A
  • OMER N/A
  • Industry
  • ONTF Computer Software: Prepackaged Software
  • OMER Biotechnology: Pharmaceutical Preparations
  • Sector
  • ONTF Technology
  • OMER Health Care
  • Exchange
  • ONTF Nasdaq
  • OMER Nasdaq
  • Market Cap
  • ONTF 230.2M
  • OMER 188.1M
  • IPO Year
  • ONTF 2021
  • OMER 2009
  • Fundamental
  • Price
  • ONTF $5.14
  • OMER $3.83
  • Analyst Decision
  • ONTF Hold
  • OMER Strong Buy
  • Analyst Count
  • ONTF 4
  • OMER 5
  • Target Price
  • ONTF $5.33
  • OMER $18.00
  • AVG Volume (30 Days)
  • ONTF 234.7K
  • OMER 1.2M
  • Earning Date
  • ONTF 08-07-2025
  • OMER 08-06-2025
  • Dividend Yield
  • ONTF N/A
  • OMER N/A
  • EPS Growth
  • ONTF N/A
  • OMER N/A
  • EPS
  • ONTF N/A
  • OMER N/A
  • Revenue
  • ONTF $145,087,000.00
  • OMER N/A
  • Revenue This Year
  • ONTF N/A
  • OMER N/A
  • Revenue Next Year
  • ONTF N/A
  • OMER $3,446.91
  • P/E Ratio
  • ONTF N/A
  • OMER N/A
  • Revenue Growth
  • ONTF N/A
  • OMER N/A
  • 52 Week Low
  • ONTF $4.35
  • OMER $2.95
  • 52 Week High
  • ONTF $7.04
  • OMER $13.60
  • Technical
  • Relative Strength Index (RSI)
  • ONTF 43.34
  • OMER 56.22
  • Support Level
  • ONTF $5.16
  • OMER $3.58
  • Resistance Level
  • ONTF $5.37
  • OMER $3.91
  • Average True Range (ATR)
  • ONTF 0.14
  • OMER 0.33
  • MACD
  • ONTF -0.01
  • OMER 0.07
  • Stochastic Oscillator
  • ONTF 10.99
  • OMER 52.74

About ONTF ON24 Inc.

ON24 Inc provides a cloud-based intelligent engagement platform that combines experiences with personalization and content, to enable sales and marketing organizations to capture and act on connected insights at scale. The Company's platform offers a portfolio of interactive and hyper-personalized digital experience products that create and capture actionable, real-time data at scale from millions of professionals to provide businesses with buying signals and behavioral insights to efficiently convert prospects into customers. It provides solutions to Financial services, Life Sciences, Life sciences, Insurance, Technology, Associations, and Others.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: